Association Between MScanFit Motor Unit Number Estimation and Clinical Function and Response to Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy

被引:0
|
作者
Hansen, Peter N. [1 ]
Mohammed, Abdullahi A. [1 ]
Markvardsen, Lars K. [2 ]
Andersen, Henning [2 ]
Tankisi, Hatice [3 ]
Sindrup, Soren H. [1 ,4 ]
Kroigard, Thomas [1 ,4 ]
机构
[1] Univ Southern Denmark, Odense Univ Hosp, Neurol Res Unit, Odense, Denmark
[2] Aarhus Univ Hosp, Dept Neurol, Aarhus, Denmark
[3] Aarhus Univ Hosp, Dept Clin Neurophysiol, Aarhus, Denmark
[4] Odense Univ Hosp, Odense Patient Data Explorat Network OPEN, Odense, Denmark
关键词
axonal loss; chronic inflammatory demyelinating polyneuropathy; immunoglobulin; motor unit number estimation; MScanFit; INTRAVENOUS IMMUNOGLOBULIN; DOUBLE-BLIND; AXONAL LOSS; POLYRADICULONEUROPATHY; SCALE; SENSITIVITY; DISABILITY; NEUROPATHY; SCLEROSIS; DIAGNOSIS;
D O I
10.1111/jns.70001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and AimsLoss of motor units in chronic inflammatory demyelinating polyneuropathy is difficult to assess by conventional nerve conduction due to collateral innervation. We aimed to assess the association between a motor unit number estimate (MUNE) derived from the compound muscle action potential (CMAP) scan using MScanFit and hand function and the clinical response to intravenous immunoglobulin (IVIG). MethodsForty-nine CIDP patients and 52 control subjects were included. CMAP scan recordings were obtained from the right abductor pollicis brevis muscle. The primary outcome was the correlation between MUNE and the duration of the nine-hole-peg test (9-HPT) at baseline and the change in the duration of the 9-HPT following treatment with IVIG. Secondary outcomes were grip strength, 10-m-walk test, six-spot-step test, medical research council sum score, inflammatory neuropathy cause and treatment sensory sum score, overall neuropathy limitations scale, and the Rasch-built overall disability scale (R-ODS). ResultsMScanFit analysis suggested both loss of motor units (reduced MUNE (p = 0.022) and N50 (p < 0.0001)) and collateral reinnervation (increased median amplitude (p < 0.0001) and size of the largest unit (p < 0.0001)) in CIDP patients compared to controls. In CIDP patients, there was a statistically significant correlation between MUNE and the duration of the 9-HPT (Spearman's r = -0.342; p = 0.016). Further, patients with a low MUNE had the largest reduction in the duration of the 9-HPT following IVIG treatment (r = -0.577; p = 0.043). MUNE also correlated significantly with R-ODS (r = -0.722; p = 0.007). InterpretationMScanFit MUNE could be a useful method for assessing motor axonal loss in CIDP, which correlates with the clinical function and treatment response.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Response to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy with only sensory symptoms
    vanDijk, GW
    Notermans, NC
    Franssen, H
    Oey, PL
    Wokke, JHJ
    JOURNAL OF NEUROLOGY, 1996, 243 (04) : 318 - 322
  • [32] Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
    Anthony Khoo
    Joseph Frasca
    David Schultz
    Biomarker Research, 7
  • [33] Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
    Khoo, Anthony
    Frasca, Joseph
    Schultz, David
    BIOMARKER RESEARCH, 2019, 7 (1)
  • [34] SERUM GLYCOBIOMARKERS DEFINING THERAPEUTIC RESPONSE TO INTRAVENOUS IMMUNOGLOBULIN IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
    Furukawa, Soma
    Fukami, Yuki
    Yokota, Ikuko
    Hanamatsu, Hisatoshi
    Furukawa, Jun-ichi
    Hane, Masaya
    Kitajima, Ken
    Sato, Chihiro
    Hiraga, Keita
    Satake, Yuki
    Yagi, Satoru
    Koike, Haruki
    Katsuno, Masahisa
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 : S92 - S92
  • [35] MOTOR UNIT NUMBER INDEX (MUNIX): IS IT RELEVANT IN CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY?
    Delmont, E.
    Benvenutto, A.
    Grapperon, A-M
    Vershueren, A.
    Campana, E. S.
    Pouget, J.
    Attarian, S.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2016, 21 (03) : 169 - 169
  • [36] Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: Clinical characteristics, electrophysiological study, and response to treatment
    Pegat, Antoine
    Boisseau, William
    Maisonobe, Thierry
    Debs, Rabab
    Lenglet, Timothee
    Psimaras, Dimitri
    Azoulay-Cayla, Ariele
    Fournier, Emmanuel
    Viala, Karine
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2020, 25 (02) : 162 - 170
  • [37] Chronic Inflammatory Demyelinating Polyneuropathy: Time to Maximal Recovery in Patients Receiving Intravenous Immunoglobulin Therapy
    Opala, Adrian R.
    Kennedy, Kevin
    Baker, Steven K.
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2020, 47 (04) : 531 - 537
  • [38] SUBCUTANEOUS IMMUNOGLOBULIN (IGPRO20) DOSE ADJUSTMENTS FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MAINTENANCE THERAPY IN CLINICAL PRACTICE
    Pulley, Michael
    Sharma, Khema
    Vu, Tuan
    Jiang, Nan
    Peltier, Amanda
    Khella, Sami
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 : S115 - S115
  • [39] RESPONSE TO INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: THE INSIGHTS QUALITY IMPROVEMENT PROJECT
    Levine, Todd
    Katz, Jonathan
    Barohn, Richard
    Saperstein, David
    Wolfe, Gil
    Katzin, Lara
    Mozaffar, Tahseen
    Dimachkie, Mazen
    Badger, Gary
    Vaughan, Leslie
    Ritt, Elissa
    Greer, Michelle
    MUSCLE & NERVE, 2016, 54 (03) : 526 - 526
  • [40] Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy
    Tortorici, Michael A.
    Yuraszeck, Theresa
    Cornblath, David
    Bril, Vera
    Hartung, Hans-Peter
    Sobue, Gen
    Lewis, Richard A.
    Merkies, Ingemar S. J.
    Lawo, John-Philip
    Praus, Michaela
    Durn, Billie L.
    Mielke, Orell
    Ma, Xuewen
    Jauslin, Petra
    Pfister, Marc
    Schaik, Ivo N.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (08): : 839 - 850